Free Trial
→ Federal Reserve Reveals Disturbing New Plan To Control Your Money (From Weiss Ratings) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
$2.84
-10.1%		$4.41
$2.67
▼
$12.32
$2.95M0.66158,659 shs7,430 shs
Lipocine Inc. stock logo
LPCN
Lipocine
$1.63
+0.6%		$2.14
$1.59
▼
$12.37
$13.39M0.4741,026 shs178,020 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$6.51
$3.96
$1.11
▼
$17.50
$27.46M0.382,778 shs1,912 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
-31.15%-31.15%-31.15%-23.08%-73.13%
Lipocine Inc. stock logo
LPCN
Lipocine
-2.41%-22.86%-28.63%-31.36%-47.91%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
+22.90%+58.87%+58.87%+50.08%-50.65%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
$2.84
-10.1%		$4.41
$2.67
▼
$12.32
$2.95M0.66158,659 shs7,430 shs
Lipocine Inc. stock logo
LPCN
Lipocine
$1.63
+0.6%		$2.14
$1.59
▼
$12.37
$13.39M0.4741,026 shs178,020 shs
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$6.51
$3.96
$1.11
▼
$17.50
$27.46M0.382,778 shs1,912 shs
7 Stocks That Could Lead the Next Market Boom Cover
7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
-31.15%-31.15%-31.15%-23.08%-73.13%
Lipocine Inc. stock logo
LPCN
Lipocine
-2.41%-22.86%-28.63%-31.36%-47.91%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
+22.90%+58.87%+58.87%+50.08%-50.65%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
1.00
SellN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
2.00
Hold$4.00145.55% Upside
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest EOCN, LPCN, and ZIVO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
10/9/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
9/24/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
9/22/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingOverweight
9/21/2026
Lipocine Inc. stock logo
LPCN
Lipocine
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingNeutral$4.00
9/3/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
DowngradeSell (D-) ➝ Sell (E+)
8/19/2026
Lipocine Inc. stock logo
LPCN
Lipocine
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
UpgradeSell (E+) ➝ Sell (D-)
7/17/2026
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access to unlock brokerage rankings
Reiterated RatingSell (E+)
(Data available from 10/14/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
N/AN/AN/AN/A$23.04 per shareN/A
Lipocine Inc. stock logo
LPCN
Lipocine
$1.98M6.78N/AN/A$2.61 per share0.62
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
$15.85K1,732.17N/AN/A($0.81) per share-8.04
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
-$10.31M-$15.18N/AN/AN/AN/A-73.68%-60.88%11/25/2026 (Estimated)
Lipocine Inc. stock logo
LPCN
Lipocine
-$9.63M-$1.79N/AN/AN/A-755.39%-64.75%-57.62%11/5/2026 (Estimated)
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
-$7.78M-$1.40N/AN/AN/AN/AN/A-2,240.92%12/2/2026 (Estimated)

Latest EOCN, LPCN, and ZIVO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
11/5/2026Q3 2026
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.39N/AN/AN/A$0.16 millionN/A
9/2/2026Q2 2026
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
-$3.12-$2.86+$0.26-$2.86N/AN/A
8/4/2026Q2 2026
Lipocine Inc. stock logo
LPCN
Lipocine
-$0.40-$0.32+$0.08-$0.32$0.21 million$0.19 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
N/AN/AN/AN/AN/A
Lipocine Inc. stock logo
LPCN
Lipocine
N/AN/AN/AN/AN/A
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
N/A
4.16
4.16
Lipocine Inc. stock logo
LPCN
Lipocine
N/A
11.48
11.48
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
N/A
0.17
0.17

Institutional Ownership

CompanyInstitutional Ownership
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
76.14%
Lipocine Inc. stock logo
LPCN
Lipocine
9.11%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
12.83%

Insider Ownership

CompanyInsider Ownership
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
19.80%
Lipocine Inc. stock logo
LPCN
Lipocine
4.69%
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
21.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
Galmed Pharmaceuticals Ltd. stock logo
EOCN
Galmed Pharmaceuticals
201.04 million836,000Not Optionable
Lipocine Inc. stock logo
LPCN
Lipocine
148.24 million7.86 millionNo Data
ZIVO Bioscience, Inc. stock logo
ZIVO
ZIVO Bioscience
104.22 million2.91 millionNot Optionable

Recent News About These Companies

Zivo Bioscience, Inc. Announces Transition to OTCID Marketplace
May 12, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260512411739/en/zivo-bioscience-inc.-announces-transition-to-otcid-marketplace/
Zivo Bioscience Inc. Wt
April 11, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/zivow
ZIVO Bioscience Provides Special Letter to Shareholders
March 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260327190358/en/ZIVO-Bioscience-Provides-Special-Letter-to-Shareholders/
Maxim Group Reaffirms Their Hold Rating on Zivo Bioscience (ZIVO)
December 15, 2025  |  theglobeandmail.comhttps://www.theglobeandmail.com/investing/markets/stocks/ZIVO/pressreleases/36474537/maxim-group-reaffirms-their-hold-rating-on-zivo-bioscience-zivo/
ZIVO Bioscience releases letter to shareholders
September 14, 2025  |  wattagnet.comW
ZIVO Bioscience CEO Letter to Shareholders Highlights Progress with Human Nutrition and Animal Therapeutic Businesses
September 10, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250910182550/en/zivo-bioscience-ceo-letter-to-shareholders-highlights-progress-with-human-nutrition-and-animal-therapeutic-businesses/
ZIVO Bioscience and Leading Global Animal Health Company to Advance ZIVO's Immune-Enhancing Compounds in Poultry
June 20, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250620564330/en/zivo-bioscience-and-leading-global-animal-health-company-to-advance-zivo%e2%80%99s-immune-enhancing-compounds-in-poultry/
University of Delaware Study Identifies Optimal Formulation of ZIVO’s Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 7, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/university-delaware-study-identifies-optimal-215400486.html
University of Delaware Study Identifies Optimal Formulation of ZIVO's Active Ingredients for Further Testing to Mitigate Avian Influenza in Poultry
May 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250506414477/en/university-of-delaware-study-identifies-optimal-formulation-of-zivo%e2%80%99s-active-ingredients-for-further-testing-to-mitigate-avian-influenza-in-poultry/
ZIVO Bioscience Plans New Study with University of Delaware to Combat Avian Influenza in Poultry
February 6, 2025  |  businesswire.comhttps://www.businesswire.com/news/home/20250206639313/en/zivo-bioscience-plans-new-study-with-university-of-delaware-to-combat-avian-influenza-in-poultry/
Zivo Bioscience issues new shares, raises $1.5 million
January 28, 2025  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/zivo-bioscience-issues-new-shares-raises-1-5-million/ar-AA1xZjTM
Tuesday's Insider Activity: Top Buys and Sells in US Stocks Revealed
January 1, 2025  |  investing.comhttps://www.investing.com/news/stock-market-news/tuesdays-insider-activity-top-buys-and-sells-in-us-stocks-revealed-93CH-3793355
ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza
December 20, 2024  |  businesswire.comhttps://www.businesswire.com/news/home/20241220941955/en/ZIVO-Bioscience-Reports-Preliminary-Efficacy-of-its-Proprietary-Active-Ingredients-in-the-Battle-Against-Avian-Influenza/
Regencell Bioscience Holdings Ltd RGC
February 1, 2024  |  morningstar.comM
ZIVO Bioscience Announces Uplisting to OTCQB Market
January 29, 2024  |  finance.yahoo.comhttps://finance.yahoo.com/news/zivo-bioscience-announces-uplisting-otcqb-130000877.html?.tsrc=rss
Ideaya Biosciences
January 18, 2024  |  forbes.comhttps://www.forbes.com/companies/ideaya-biosciences/
Dare Bioscience Inc DARE
January 14, 2024  |  morningstar.comM
Zivo Bioscience Inc (ZIVO) USD0.001
November 11, 2023  |  hl.co.ukhttps://www.hl.co.uk/shares/shares-search-results/z/zivo-bioscience-inc-usd1.001/costs
Zivo Bioscience (ZIVO) Price Target Increased by 500.00% to 36.72
November 1, 2023  |  msn.comhttps://www.msn.com/en-us/money/markets/zivo-bioscience-zivo-price-target-increased-by-50000-to-3672/ar-AA1jflXo
Zivo Bioscience Inc ZIVO
November 1, 2023  |  morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Galmed Pharmaceuticals stock logo

Galmed Pharmaceuticals NASDAQ:EOCN

$2.84 -0.32 (-10.13%)
As of 01:01 PM Eastern

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.

Lipocine stock logo

Lipocine NASDAQ:LPCN

$1.63 +0.01 (+0.56%)
As of 01:25 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.

ZIVO Bioscience stock logo

ZIVO Bioscience NASDAQ:ZIVO

$6.51 0.00 (0.00%)
As of 10/13/2026 03:53 PM Eastern

ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging. The company was formerly known as Health Enhancement Products, Inc. and changed its name to ZIVO Bioscience, Inc. in October 2014. ZIVO Bioscience, Inc. is headquartered in Bloomfield Hills, Michigan.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas